Solving humanity’s biggest problems has been OpenAI’s stated reason for pursuing artificial general intelligence since its 2015 founding, and over time, life science challenges have crystallized as core parts of its vision. In February 2025, CEO Sam Altman wrote that “we can now imagine a world where we cure all diseases,” and by that September… The post OpenAI research and product leads detail GPT-Rosalind capabilities and benchmarks appeared first on Research & Development World .